Gold prices slip slightly after recent gains; U.S. data eyed
SAN DIEGO—Onyia Jude, Chief Scientific Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently executed stock transactions involving the company's common shares. According to a recent SEC filing, Jude sold a total of 2,879 shares in two separate transactions on February 13, 2025. The transactions come as the stock trades near its 52-week low of $110.95, down approximately 16% year-to-date.
The first transaction involved the sale of 1,432 shares at a weighted average price of $116.8335, yielding approximately $167,305. The second transaction saw Jude selling an additional 1,447 shares at a weighted average price of $116.7471, resulting in proceeds of about $168,933. These transactions were conducted under a Rule 10b5-1 trading plan, which provides a pre-determined schedule for buying or selling stock. For comprehensive insider trading analysis and more insights, InvestingPro subscribers can access detailed trading patterns and company health metrics.
In addition to the sales, Jude acquired 5,407 shares through the exercise of stock options and restricted stock units, although these acquisitions were conducted at no cost.
Following these transactions, Jude holds a total of 18,089 shares of Neurocrine Biosciences common stock.
In other recent news, Neurocrine Biosciences has been the focus of several analyst reports, following the company's recent earnings announcement. Deutsche Bank (ETR:DBKGn) initiated coverage on Neurocrine with a Hold rating and a price target of $138, citing the company's fair valuation in light of its current treatments, Ingrezza and Crensessity. Meanwhile, UBS maintained a Buy rating but reduced its price target to $154, following a significant decline in the company's shares and lowered expectations for Ingrezza.
Guggenheim also maintained a Buy rating but lowered its target to $163 after the company's fourth-quarter sales report showed Ingrezza sales slightly below consensus estimates. H.C. Wainwright followed suit, adjusting its price target to $185 while maintaining a Buy rating, in response to the company's lower-than-expected full-year 2025 Ingrezza revenue guidance.
These recent developments come after Neurocrine reported revenues that fell short of estimates, despite a 26% growth in Ingrezza net product sales for the full year of 2024 compared to the previous year. The company's full-year 2025 net product sales guidance of $2.5 - $2.6 billion also fell below consensus estimates. Despite these challenges, Neurocrine Biosciences is advancing its clinical pipeline and is expected to initiate pivotal trials for their '845 program in Major Depressive Disorder and '568 program in schizophrenia in the first half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.